Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
600-900 mg IV every 8 hours, or 900 mg IV every 12 hours.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
Terminal elimination half-life is 2.4–3.0 hours in adults with normal hepatic and renal function; prolonged in severe hepatic impairment (up to 8–10 hours) and in neonates (8–20 hours).
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Approximately 10% of administered dose excreted renally as active drug; significant biliary/fecal elimination (about 40% as active drug and metabolites) via enterohepatic circulation.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic